Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Director Stephen M. Dow Purchases 25,000 Shares of Stock

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Director Stephen M. Dow purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Alder BioPharmaceuticals, Inc. (ALDR) opened at 11.55 on Wednesday. The stock’s 50 day moving average is $15.05 and its 200 day moving average is $19.60. Alder BioPharmaceuticals, Inc. has a 12-month low of $10.05 and a 12-month high of $36.48. The company’s market cap is $582.24 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $1.04. During the same quarter in the prior year, the company earned ($0.76) EPS. On average, equities analysts forecast that Alder BioPharmaceuticals, Inc. will post ($6.27) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Director Stephen M. Dow Purchases 25,000 Shares of Stock” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/07/19/alder-biopharmaceuticals-inc-nasdaqaldr-director-stephen-m-dow-purchases-25000-shares-of-stock.html.

Institutional investors have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. acquired a new stake in Alder BioPharmaceuticals during the second quarter valued at approximately $402,000. Nuveen Asset Management LLC raised its position in Alder BioPharmaceuticals by 36.6% in the first quarter. Nuveen Asset Management LLC now owns 66,224 shares of the biopharmaceutical company’s stock valued at $1,377,000 after buying an additional 17,760 shares during the last quarter. Janus Capital Management LLC raised its position in Alder BioPharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company’s stock valued at $107,473,000 after buying an additional 230,044 shares during the last quarter. Credit Suisse AG raised its position in Alder BioPharmaceuticals by 19.8% in the first quarter. Credit Suisse AG now owns 243,807 shares of the biopharmaceutical company’s stock valued at $5,071,000 after buying an additional 40,260 shares during the last quarter. Finally, Redmile Group LLC raised its position in Alder BioPharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock valued at $39,726,000 after buying an additional 989,336 shares during the last quarter.

A number of equities analysts recently commented on the stock. UBS AG assumed coverage on shares of Alder BioPharmaceuticals in a research note on Friday, May 5th. They issued a “sell” rating and a $13.00 price objective for the company. Needham & Company LLC set a $36.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “buy” rating in a research note on Monday. Leerink Swann reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Alder BioPharmaceuticals in a research note on Monday, June 12th. Aegis reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Alder BioPharmaceuticals in a research note on Tuesday, April 25th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Alder BioPharmaceuticals in a research note on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $35.00.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply